Is Innova Captab overvalued or undervalued?

As of 22 August 2025, the valuation grade for Innova Captab has moved from fair to attractive, indicating a more favorable outlook for the company. The stock is currently considered undervalued. Key ratios include a PE ratio of 39.77, an EV to EBITDA of 27.70, and a ROE of 13.37%.
Innova Captab's valuation stands out when compared to peers such as Sun Pharma, which is deemed expensive with a PE ratio of 34.36, and Cipla, which is also attractive but has a significantly lower PE ratio of 23.83. Despite a recent decline in stock performance relative to the Sensex, with a year-to-date return of -18.3% compared to the Sensex's 4.05%, the company's strong ratios suggest it is positioned well within its industry.